Iteos Therapeutics Earnings Estimate

By analyzing Iteos Therapeutics' earnings estimates, investors can diagnose different trends across Iteos Therapeutics' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Iteos Therapeutics is based on EPS before non-recurring items and includes expenses related to employee stock options. Iteos Therapeutics is projected to generate -1.06615 in earnings per share on the 31st of December 2025. Iteos Therapeutics earnings estimates module stress-tests analyst consensus about projected Iteos Therapeutics EPS (Earning Per Share) to derive its highest and lowest estimates based on its historical volatility. Many public companies, such as Iteos Therapeutics, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Iteos Therapeutics' earnings estimates, investors can diagnose different trends across Iteos Therapeutics' analyst sentiment over time as well as compare current estimates against different timeframes. Gross Profit Margin is likely to gain to 1.07 in 2024, whereas Gross Profit is likely to drop slightly above 11.1 M in 2024. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Iteos Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. For more information on how to buy Iteos Stock please use our How to Invest in Iteos Therapeutics guide.